Tags : (galcanezumab-gnlm)

Eli Lilly Reports Results of Emgality (galcanezumab-gnlm) in Three P-III

Shots: The P-III studies include REGAIN and EVOLVE-1 & 2 assessing Emgality vs PBO in patients with chronic and episodic migraine respectively Post-hoc analyses results: reductions in disability in chronic migraine (20.3% vs 13.9%); @6mos. little/no disability in episodic migraine (44.0% vs 26.5%); improvement in daily functioning Emgality is a mAb targeting CGRP and has […]Read More

Eli Lilly Reports Results of Emgality (galcanezumab-gnlm) in Two P-III

Shots: The P-III EVOLVE-1 and EVOLVE-2 studies result involves assessing of Emgality (galcanezumab-gnlm, 120mg & 240mg) vs PBO in 1,700 patients with low (4 to<8 monthly migraine headache days) and high (8-14 monthly migraine headache days) frequency episodic migraine The collective studies result demonstrated improvement in both subgroups with mean % of patients with ≥50%, […]Read More